{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018914","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.259440+00:00","generated_at":"2026-06-08T03:50:22.533392+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share","bullets":["Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.","Q3 net loss $44.3M ($0.74 per share) vs $37.3M ($0.83) prior year; license revenue $5.1M.","R&D expenses rose 65% to $27.9M driven by manufacturing costs and Janssen collaboration changes.","Cash $64.4M plus $22M Janssen receivables and $30M Sanofi investment; runway into mid-2025.","Phase 3 XLRP trial fully enrolled with IND transferred to Janssen; Phase 2 Xerostomia and Parkinson's studies ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018914","json":"https://secwatch.observer/filing/0001558370-23-018914.json","markdown":"https://secwatch.observer/filing/0001558370-23-018914.md","text":"https://secwatch.observer/filing/0001558370-23-018914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/0001558370-23-018914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/mgtx-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:50:22.533392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd0706055367cd192e3500aa31daa6cafb0e93bf","claim":"MeiraGTx Holdings plc reported the quarter ended September 30, 2023 results: revenue $5.1 million.","evidence_excerpt":"License revenue was $5.1 million for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/0001558370-23-018914-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}